secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001104659-25-049411
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27
------------------------------------------------------------------------

- Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).
- Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).
- LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.
- FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.
- Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/0001104659-25-049411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-049411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer